† Deaths in LEAD-2: one in the run-in period, one after trial correction for hepatocellular carcinoma; deaths in LEAD-3: car accident. ‡ Only one out of five major hypoglycemic episodes ...

GLP-1 drugs also slow digestion, and GLP-1 makers warn of constipation and other potential digestive side effects such as nausea, diarrhea, stomach pain, vomiting, bloating and heartburn. Other common ...

Learn about the financial strain caused by the skyrocketing demand and costs of GLP-1 drugs, and how health plans and providers are struggling to balance it.

We know now that glucagon-like peptide 1 (GLP-1) drugs for obesity bring with them a whole host of other potential benefits, as well as a handful of side effects. But new research has brought a ...

After just a few years on the market, a new wave of GLP-1 drugs approved for weight loss ... The new data also found possible side effects that were not previously known. Soundside spoke with ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Study finds that a significant proportion of adults prescribed GLP-1 RAs for weight management discontinue treatment within a ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator instructions] I would now like to turn the conference over to your host, Mike Czapar, ...

People who take weight-loss drugs based on GLP-1 ... effects needs exploration, Prof O'Rahilly suggested that low blood pressure and kidney stones could result from known gastrointestinal side ...

Despite their remarkable efficacy for many populations, GLP-1s have a relatively low persistence rate over time, due to a combination of factors, including costs, side effects, and, yes ...